Eli Lilly and Company will invest $1 billion to establish India as a central hub for its global supply chain.
The pharmaceutical giant will utilize local contract manufacturing operations to produce and export medicines to international markets.
Eli Lilly also plans to introduce its Alzheimer's treatment donanemab and the experimental oral weight-loss drug orforglipron to the Indian market, subject to regulatory approvals.
This expansion aims to leverage India's manufacturing capabilities to meet increasing worldwide demand for the company's product portfolio.